0000000001225517

AUTHOR

Florence Joly

showing 2 related works from this author

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and pac…

2018

Summary Purpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patients with metastatic breast cancer (MBC). Methods This phase Ib study enrolled 35 MBC patients (first line or higher) with HER3-positive and HER2-low (immunohistochemistry 1+ to 2+ and in-situ hybridization negative) tumors. Patients received lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose [LD] followed by 420 mg in Cohorts 1 and 2; 420 mg without LD in Cohort 3) every 3 weeks, plus paclitaxel (8…

0301 basic medicineOncologyMaleReceptor ErbB-3Receptor ErbB-2Medizinchemistry.chemical_compound0302 clinical medicineErbB3Phase I StudiesAntineoplastic Combined Chemotherapy ProtocolsMedicinePharmacology (medical)skin and connective tissue diseasesMiddle AgedMetastatic breast cancerMetastatic breast cancerDiarrheaOncologyPaclitaxel030220 oncology & carcinogenesisMarcadors bioquímicsCohortFemalePertuzumabmedicine.symptommedicine.drugAdultDiarrheamedicine.medical_specialtyLoperamidePaclitaxelMama -- Càncer -- TractamentAntineoplastic AgentsBreast NeoplasmsHypokalemiaAntibodies Monoclonal HumanizedLoading dosePolymorphism Single Nucleotide03 medical and health sciencesPhase IHuman epidermal growth factor receptor 3 (HER3)Internal medicineHumansAgedPharmacologyPertuzumabbusiness.industryBiomarkerLumretuzumabmedicine.disease030104 developmental biologychemistryHuman epidermal growth factor receptor 2 (HER2)businessHeregulin (HRG)
researchProduct

Long term gynaecological cancer survivors in Cote d'Or: health-related quality of life, social and professional reinsertion

2018

IF 2,392 (2017); International audience

Quality of lifeGynaecological cancer[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics[SDV.CAN] Life Sciences [q-bio]/CancerProfessional reinsertion[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics
researchProduct